Janssen to Discontinue Hepatitis C Development Program

Food and Healthcare Press Releases Monday September 11, 2017 12:44
CORK, Ireland--11 Sep--PRNewswire/InfoQuest
  • Viral Hepatitis Research and Development to Focus on Addressing Significant Unmet Needs in Chronic Hepatitis B

Janssen Sciences Ireland UC (Janssen), today announced a strategic decision to discontinue further development of the investigational hepatitis C treatment regimen JNJ-4178, a combination of three direct acting antivirals - AL-335, odalasvir and simeprevir. The ongoing phase II studies with JNJ-4178 will be completed as planned, but there will be no additional development thereafter. This decision was made in light of the increasing availability of a number of highly effective therapies addressing the medical need in hepatitis C.

(Logo: http://photos.prnewswire.com/prnh/20140324/NY88746LOGO )

"Going forward, our hepatitis R&D efforts will focus on chronic hepatitis B, where a high unmet medical need still exists. Our scientists are energized by this challenge and our research ambition is to achieve a functional cure of hepatitis B which affects over a quarter of a billion people globally," said Lawrence M. Blatt, Ph.D., Global Therapeutic Area Head, Infectious Disease Therapeutics, Janssen. "At Janssen, we focus our research and development on areas of greatest unmet medical need where we can combine our excellent internal science with the best available external innovation to bring optimized solutions and maximum benefit to patients."

Janssen pioneered the advancement of the first innovations in hepatitis C for nearly a decade when it co-developed telaprevir, a first-in-class protease inhibitor used in combination therapy for the treatment of chronic hepatitis C virus.[1] In collaboration with Medivir AB, Janssen subsequently developed and launched the second generation protease inhibitor OLYSIO(R) (simeprevir),[2] which is approved in countries around the world.

Today, people living with hepatitis C have a much more diverse range of therapies available following a wave of innovative treatments securing approval. For most, the standard of care for hepatitis C therapy has a duration of 8-12 weeks offering a cure to around 92-100% of people treated.[3]

About Janssen

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at http://www.janssen.com and follow us at @JanssenGlobal.

References

1. Janssen. INCIVO(R) Approved in Europe Offering High Cure Rates for Genotype-1 Chronic Hepatitis C Compared to Standard of Care. Available at: https://www.jnj.com/media-center/press-releases/incivo-telaprevir-approved-in-europe-offering-higher-cure-rates-for-genotype-1-chronic-hepatitis-c-compared-to-standard-treatment Last accessed: September 2017.

2. Janssen. OLYSIO(TM) (simeprevir) Receives FDA Approval for Combination Treatment of Chronic Hepatitis C. Available at: https://www.jnj.com/media-center/press-releases/olysio-simeprevir-receives-fda-approval-for-combination-treatment-of-chronic-hepatitis-c Last accessed: September 2017.

3. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. Journal of Hepatology. 2017: 66(1):153-194.
Source: Janssen

Latest Press Release

Menarini Ricerche Announces New Positive Results in Acute Myeloid Leukemia Cell Lines for MEN1112/OBT357 at the 60th Annual SIC Meeting

Menarini Ricerche will present tomorrow, September 20th, at the 60th Annual Meeting of the Italian Cancer Society (SIC), new preclinical data showing that pre-treatment with 5-Azacytidine and Decitabine enhances the Antibody-dependent cellular...

Experts Call for Improved Identification of #High Burden# Rosacea Patients in Everyday Practice

- Additional analysis of global survey data reveals quality of life is impacted by several factors extending beyond severity of rosacea alone Additional analysis of a global survey conducted and presented earlier this year, as an expert-authored report...

BookDoc collaborates with Chow Tai Fook: Get more rewards by staying active together with Chow Tai Fook

Chow Tai Fook is collaborating with BookDoc, the largest integrated healthcare app in Southeast Asia by healthcare network in giving more rewards to BookDoc users for maintaining an active healthy lifestyle. Users can now enjoy discounts and redeem...

MEDICAL WINGS THAILAND BASED AIR AMBULANCE OPERATOR ACHIEVES FULL ACCREDITATION FROM CAMTS AND CAMTS EU AND BECOMES THE FIRST OPERATOR IN ASIA TO ACHIEVE THE #DUAL ACCREDITATION

Medical Wings, the air ambulance division of Siam Land Flying Company, a subsidiary company of Charoen Pokphand Group (C.P. Group), is proud to achieve full re-accreditation of its existing CAMTS approval as well as attaining the new CAMTS EU...

Photo Release: CGH Group Hospital held the event Happy Life with Healthy Bone and Joints Seminar in Yangon, Myanmar.

CGH Group Hospital recently held a live health talk in Yangon, Myanmar to highlight the important health issues on bone and joints for all Myanmar people. A team of medical experts led by Dr. Wanchai Sirisereewan (4th from left), CGH's Orthopedic Surgeon...

Related Topics